Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNJ1 | P48048 | 9/20 | 0.38 |
| ▸ | KCNH2 | Q12809 | 6/20 | 0.36 |
| ▸ | GPR119 | Q8TDV5 | 5/20 | 0.36 |
| ▸ | SSTR2 | P30874 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | F11 | P03951 | 4/20 | 0.34 |
| ▸ | KLKB1 | P03952 | 4/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14141945 | 0.91 | ALDH1A1 (0.36) | KCNJ1KCNH2GPR119ALDH1A1HPGD | |
| SCHEMBL10179902 | 0.90 | ALDH1A1 (0.36) | KCNJ1KCNH2GPR119SSTR2ALDH1A1 | |
| SCHEMBL10179177 | 0.89 | EGLN1 (0.34) | KCNJ1KCNH2GPR119ALDH1A1HPGD | |
| SCHEMBL14141977 | 0.89 | KCNJ1 (0.36) | KCNJ1KCNH2GPR119SSTR2ALDH1A1 | |
| SCHEMBL10179766 | 0.89 | GPR119 (0.49) | KCNH2GPR119F11 | |
| SCHEMBL12544773 | 0.89 | GPR119 (0.39) | KCNJ1KCNH2GPR119SSTR2ALDH1A1 | |
| SCHEMBL10181205 | 0.86 | ALDH1A1 (0.38) | KCNJ1KCNH2GPR119ALDH1A1HPGD | |
| SCHEMBL10187772 | 0.85 | P2RY14 (0.33) | KCNJ1KCNH2GPR119F11 | |
| SCHEMBL10179406 | 0.84 | EGLN1 (0.35) | KCNH2 | |
| SCHEMBL10179456 | 0.81 | PRMT5 (0.38) | KCNJ1KCNH2GPR119ALDH1A1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120245344-A1 | GPR119 AGONIST | NIPPON CHEMIPHAR CO., LTD. (JP) | 2012-09-27 | — | — | US | disclosed |
| EP-2474540-A1 | GPR119 AGONIST | Nippon Chemiphar Co., Ltd. (JP) | 2012-07-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120245344-A1 | GPR119 AGONIST | GPR119, GPR4, GPR55 | KCNJ1 789/4885KCNH2 484/4885GPR119 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.